Angiokeratoma corporis diffusum--Fabry disease: historical review from the original description to the introduction of enzyme replacement therapy.
about
Successful management of enzyme replacement therapy in related fabry disease patients with severe adverse events by switching from agalsidase Beta (fabrazyme(®)) to agalsidase alfa (replagal (®)).The Fabry disease-associated lipid Lyso-Gb3 enhances voltage-gated calcium currents in sensory neurons and causes pain.Descriptive epidemiology of Fabry disease among beneficiaries of the Specified Disease Treatment Research Program in Japan.Clinical observation of patients with Fabry disease after switching from agalsidase beta (Fabrazyme) to agalsidase alfa (Replagal).Automatic lane segmentation in TLC images using the continuous wavelet transform.Serum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy
P2860
Angiokeratoma corporis diffusum--Fabry disease: historical review from the original description to the introduction of enzyme replacement therapy.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Angiokeratoma corporis diffusu ...... of enzyme replacement therapy.
@ast
Angiokeratoma corporis diffusu ...... of enzyme replacement therapy.
@en
type
label
Angiokeratoma corporis diffusu ...... of enzyme replacement therapy.
@ast
Angiokeratoma corporis diffusu ...... of enzyme replacement therapy.
@en
prefLabel
Angiokeratoma corporis diffusu ...... of enzyme replacement therapy.
@ast
Angiokeratoma corporis diffusu ...... of enzyme replacement therapy.
@en
P1476
Angiokeratoma corporis diffusu ...... of enzyme replacement therapy.
@en
P2093
P577
2002-01-01T00:00:00Z